Clinical trials: sponsored by Haisco Pharmaceutical Group Co., Ltd.
IgA Nephropathy (IgAN)
A Study to Evaluate the Long-Term Safety and Efficacy of HSK39297 Tablets in Primary IgA Nephropathy
This is a Phase II, multicenter, open-label study. Eligible subjects who have completed the HSK39297-202 study will be enrolled.Starting dose is 200 mg QD.Dose may be increased to 300 mg QD after 8-12 weeks of stable 200 mg QD…
- Trial name
- NCT07616700
- Testing
- HSK39297 200mgQD, HSK39297 300mgQD
- Where
- 2 sites in China
- Volunteers
- 73 people
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
General Anesthetic
HSK3486 (Cipepofol) Injectable Emulsion for Induction of General Anesthesia in Pediatric Subjects Undergoing Elective Surgery
This multicenter, randomized, double-blinded, propofol-controlled Phase 3b study enrolls pediatric subjects aged 3-17 years undergoing elective surgery with endotracheal intubation.
- Trial name
- NCT07510945
- Testing
- HSK3486, propofol
- Volunteers
- 400 people
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
Anesthesia
A Multicenter, Open, Controlled, Phase III Clinical Study to Evaluate the Efficacy and Safety of Cipepofol Injection for General Anesthesia in Pediatric Patients Undergoing Elective Surgery
A multicenter, open, controlled, Phase III clinical study to evaluate the efficacy and safety of Cipepofol injection for general anesthesia in pediatric patients undergoing elective surgery
- Trial name
- NCT06391931
- Testing
- Cipepofol, Propofol
- Where
- China
- Volunteers
- 190 people
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.